Home / Pharmaceutical company intelligence
Pearl Pharmaceuticals logo
Pharmaceutical company intelligence

Pearl Pharmaceuticals

Pharmaceutical manufacturer and marketer · Islamabad · Pakistan

Islamabad pharmaceutical manufacturer and marketer with a diversified portfolio and local manufacturing facility.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check8 Sep 2026Latest source-check date across this published portfolio
Latest effective price date21 Apr 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer and marketer
Address
Plot No. 204, Street No. 1, I-10/3 Industrial Area, Islamabad, Pakistan
Phone
+92 51 4434775-76; +92 51 4448534; +92 51 4441140
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000479 Pearl Pharmaceuticals. · Islamabad
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000479 119 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx119public portfolio records represented
REG96unique registrations represented
IDX80indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR118current validated price records
G46generic molecules in indexed catalogue
DF10dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage99%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixPearl PharmaceuticalsShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pearl-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives80 · 68%Dermatology10 · 8%Gastrointestinal & hepatology6 · 5%Cardiovascular5 · 4%Pain & musculoskeletal4 · 3%Respiratory & allergy4 · 3%Fluids & supportive care3 · 3%Other therapeutic areas6 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioPearl PharmaceuticalsDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pearl-pharmaceuticalsGenerated 23 Sep 2026118presentationsTablet42 · 36%Injection18 · 15%Capsule16 · 14%Suspension13 · 11%Cream12 · 10%Lotion8 · 7%Other forms9 · 8%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionPearl PharmaceuticalsCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pearl-pharmaceuticalsGenerated 23 Sep 2026111comparable productsBelow peer median19 · 17%Near peer median43 · 39%Above peer median49 · 44%Company median price position+1.4%Lowest-price equivalents5Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsPearl PharmaceuticalsCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/pearl-pharmaceuticalsGenerated 23 Sep 2026Neutro Pharma (Pvt.) Ltd.,33 shared72% overlapNabiqasim Industries (Pvt) Ltd.,32 shared70% overlapPharmasol (Pvt) Ltd.30 shared65% overlapZafa Pharmaceutical Laboratories (P…30 shared65% overlapValor Pharmaceuticals30 shared65% overlapNovaMed Pharmaceuticals(Pvt.)Ltd30 shared65% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives80 products · 68%
Dermatology10 products · 8%
Gastrointestinal & hepatology6 products · 5%
Cardiovascular5 products · 4%
Pain & musculoskeletal4 products · 3%
Respiratory & allergy4 products · 3%
Fluids & supportive care3 products · 3%
Vitamins, minerals & nutrition2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins16 products · 14%
Antifungals16 products · 14%
Macrolide antibacterials9 products · 8%
Fluoroquinolone antibacterials7 products · 6%
First-generation cephalosporins7 products · 6%
Topical corticosteroids / anti-inflammatory dermatologics6 products · 5%
Antivirals6 products · 5%
Antimalarials5 products · 4%
Formulation footprint

Dosage forms

Tablet42 products
Injection18 products
Capsule16 products
Suspension13 products
Cream12 products
Lotion8 products
Syrup4 products
Gel2 products
Ointment2 products
Drops1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ClozoleClotrimazole 5presentations 0.1 g, 0.3 g, 500 mg · Cream, Lotion #2 PtroxCeftriaxone 5presentations 1 g, 2 g, 250 mg, 500 mg · Injection #3 XimcefCefixime 5presentations 100 mg/5 mL, 200 mg, 200 mg/5 mL, 400 mg · Suspension, Capsule #4 HydrovateHydrocortisone 4presentations 1 %, 1% · Cream #5 LeksusLoratadine 4presentations 10 mg, 5 mg/5 mL · Tablet, Syrup #6 LinzopearlLinezolid 4presentations 100 mg/5 mL, 400 mg, 600 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1917% of comparable products
Near market median43within ±5% of median
Above market median4944% of comparable products
Lowest-price equivalents5ties included
Company median price position +1.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Colbex 500 mgParacetamol · Tablet · 100x10's PKR 1.55/tablet-57.3% vs market median Amlobest 5 mgAmlodipine · Tablet · 2x10's PKR 5.91/tablet-45.5% vs market median Amlobest 5 mgAmlodipine · Tablet · 3x10's PKR 5.91/tablet-45.5% vs market median Monolexin Dry 100 mgCephalexin · Oral drops · 10ml PKR 9.84/mL-22.0% vs market median Hydrovate 1 %Hydrocortisone · Cream · 20gm PKR 4.54/g-21.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 33shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 32shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 30shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 30shared generics Valor Pharmaceuticals219 products · 97 generics 30shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 30shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers95Distinct registrations among indexed, published, presentation-validated products only
Verified price observations119
Products with a verified price118
Products with multiple price observations1
Source records with multiple versions118
Latest portfolio source check8 Sep 2026
Latest effective price date21 Apr 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

96 unique registration(s) · 80 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Pcef Cefotaxime 1 g Injection 1's 055874 PKR 286.41 PKR 286.41/vial/unit Near median
Ptrox Ceftriaxone 250 mg Injection 1's 032550 PKR 161.55 PKR 161.55/vial/unit 16% below median
Ptrox Ceftriaxone 500 mg IM injection 1's 032551 PKR 266.09 PKR 266.09/vial/unit 19% below median
Ptrox Ceftriaxone 1 g Injection 1's 032552 PKR 532.17 PKR 532.17/vial/unit 12% below median
Ptrox Ceftriaxone 500 mg Injection 1's 119171 PKR 334.58 PKR 334.58/vial/unit Near median
Ptrox Ceftriaxone 2 g Injection 1's 119172 PKR 885.65 PKR 885.65/vial/unit 10% above median
Scabi-Pearl Permethrin 5% Cream 30gm 059419 PKR 116.98 PKR 3.90/g Near median
Scabi-Pearl Permethrin 5% Lotion 120ml 109425 PKR 314.53 PKR 2.62/mL Near median
Scabi-Pearl Permethrin 5 % Lotion 60ml 109425 PKR 157.45 PKR 2.62/mL Near median
Terbipearl Terbinafine 1 % Cream 10gm 106539 PKR 280.56 PKR 28.06/g Near median
Terbipearl Lotion Terbinafine 1 % Lotion 60ml 121520 PKR 1,469.33 PKR 24.49/mL 8% below median
Terbipearl Lotion Terbinafine 1 % Lotion 10ml 121520 PKR 266.11 PKR 26.61/mL 9% above median
Terbipearl Lotion Terbinafine 1 % Lotion 20ml 121520 PKR 532.23 PKR 26.61/mL 9% above median
Terbipearl Lotion Terbinafine 1 % Lotion 30ml 121520 PKR 798.34 PKR 26.61/mL 9% above median
Tevoflox Levofloxacin 250 mg Tablet 1x10's 033355 PKR 475.16 PKR 47.52/tablet Near median
Tevoflox Levofloxacin 500 mg Tablet 1x10's 033356 PKR 790.65 PKR 79.07/tablet Near median
Tevoflox Levofloxacin 750 mg Tablet 10's 068560 PKR 931.30 PKR 93.13/tablet Near median
Virolite Aciclovir 5% w/w Ointment 10 gm 072032 PKR 370.62 PKR 37.06/g No comparator
Ximcef Cefixime 200 mg/5 mL Dry suspension 30ml 056085 PKR 385.25 PKR 12.84/mL Near median
Ximcef Cefixime 100 mg/5 mL Dry suspension 30ml 056086 PKR 314.81 PKR 10.49/mL Near median
Ximcef Cefixime 200 mg Capsule 5's 062967 PKR 313.61 PKR 62.72/capsule Near median
Ximcef Cefixime 200 mg Capsule 10's 062967 PKR 614.66 PKR 61.47/capsule Near median
Ximcef Cefixime 400 mg Capsule 5's 062968 PKR 564.12 PKR 112.82/capsule Near median
Zatrocin Azithromycin 250 mg Capsule 1x10's 032899 PKR 484.65 PKR 48.47/capsule Near median
Zatrocin Azithromycin 200 mg/5 mL Dry suspension 30ml 068887 PKR 614.66 PKR 20.49/mL Near median
Zatrocin Azithromycin 200 mg/5 mL Suspension 15 ml 068887 PKR 313.61 PKR 20.91/mL Near median
Zatrocin Azithromycin 500 mg Tablet 6's 104782 PKR 548.71 PKR 91.45/tablet 8% above median
Zepack Azithromycin 250 mg Tablet 6's 068559 PKR 285.09 PKR 47.52/tablet Near median
ZoloPearl Cefazolin 500 mg Injection 1's 084384 PKR 114.03 PKR 114.03/vial/unit 9% below median
ZoloPearl Cefazolin 1 g Injection 1's 084385 PKR 190.07 PKR 190.07/vial/unit 10% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Pearl Pharmaceuticals — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/pearl-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.